Anticancer therapy

Norenberg, Jeffrey P.

Title: Anticancer therapy

Abstract

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Inventors:: Norenberg, Jeffrey P.

Issue Date:: 2019-01-08

Research Org.:: STC.UNM, Albuquerque, NM (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1496591

Patent Number(s):: 10172967

Application Number:: 15/427,355

Assignee:: STC.UNM (Albuquerque, NM)

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K2300/00 - Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K31/7068 - having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K38/31 - Somatostatins
A61K45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K51/08 - Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
A61K51/083 - {the peptide being octreotide or a somatostatin-receptor-binding peptide}
A61K51/088 - {conjugates with carriers being peptides, polyamino acids, proteins

Show less

DOE Contract Number:: FG01-001NE23554

Resource Type:: Patent

Resource Relation:: Patent File Date: 2017 Feb 08

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES

Citation Formats


                    Norenberg, Jeffrey P. Anticancer therapy.  United States: N. p., 2019. 
        Web.

Copy to clipboard


                    Norenberg, Jeffrey P. Anticancer therapy.  United States.

Copy to clipboard


                    Norenberg, Jeffrey P. Tue .  
        "Anticancer therapy".  United States.  https://www.osti.gov/servlets/purl/1496591.

Copy to clipboard


                    
@article{osti_1496591,

  title        = {Anticancer therapy},

  author       = {Norenberg, Jeffrey P.},

  abstractNote = {A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {2019},

  month        = {1}

}

Copy to clipboard

Patent:

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Borch, Richard F.; Schmalbach, Therese K.
US Patent Document 4,938,949
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/4938949

Preclinical Evaluation of the α-Particle Generator Nuclide ²²⁵Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
journal, June 2008

Miederer, M.; Henriksen, G.; Alke, A.
Clinical Cancer Research, Vol. 14, Issue 11, p. 3555-3561
https://doi.org/10.1158/1078-0432.CCR-07-4647

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

Rolleman, Edgar; Melis, Marleen; Valkema, Roelf
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031
https://doi.org/10.1007/s00259-009-1282-y

Somatostatin in the central nervous system: Physiology and pathological modifications
journal, January 1986

Epelbaum, Jacques
Progress in Neurobiology, Vol. 27, Issue 1
https://doi.org/10.1016/0301-0082(86)90012-2

Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
journal, August 2003

Reubi, Jean Claude
Endocrine Reviews, Vol. 24, Issue 4
https://doi.org/10.1210/er.2002-0007

Biochemical and Functional Properties of Somatostatin Receptors
journal, June 1992

Rens-Domiano, Stephanie; Reisine, Terry
Journal of Neurochemistry, Vol. 58, Issue 6
https://doi.org/10.1111/j.1471-4159.1992.tb10938.x

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik
Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880
https://doi.org/10.1021/ar800188e

Long-term toxicity of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in rats
journal, September 2006

Rolleman, Edgar; Krenning, Eric; Bernard, Bert
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227
https://doi.org/10.1007/s00259-006-0232-1

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
journal, January 1973

Brazeau, P.; Vale, W.; Burgus, R.
Science, Vol. 179, Issue 4068
https://doi.org/10.1126/science.179.4068.77

Hypothalamic hormones: from neuroendocrinology to cancer therapy
journal, January 1994

Schally, Andrew V.
Anti-Cancer Drugs, Vol. 5, Issue 2
https://doi.org/10.1097/00001813-199404000-00001

Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype
journal, September 1993

Yamada, Y.; Kagimoto, S.; Kubota, A.
Biochemical and Biophysical Research Communications, Vol. 195, Issue 2
https://doi.org/10.1006/bbrc.1993.2122

The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001

Waldherr, C.; Pless, M.; Maecke, H.
Annals of Oncology, Vol. 12, Issue 7, p. 941-945
https://doi.org/10.1023/A:1011160913619

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

DeJong, Marion; Krenning, Eric P.; Van Hagen, Petrus Martinus
US Patent Document 7,202,330
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7202330

Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study
journal, July 1996

Gibril, Fathia
Annals of Internal Medicine, Vol. 125, Issue 1
https://doi.org/10.7326/0003-4819-125-1-199607010-00005

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
journal, April 1993

Corness, Jacquie D.; Demchyshyn, Lidia L.; Seeman, Philip
FEBS Letters, Vol. 321, Issue 2-3
https://doi.org/10.1016/0014-5793(93)80124-D

Somatostatin analogs for the treatment of cancer
patent, November 2001

Burman, Anand C.; Prasad, Sudhanand; Mukherjee, Rama
US Patent Document 6,316,414
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6316414

Cyclic peptide somatostatin analogs
patent, August 1999

Dean, Richard T.; McBride, William; Lister-James, John
US Patent Document 5,932,189
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5932189

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
journal, March 1986

Cai, R. Z.; Szoke, B.; Lu, R.
Proceedings of the National Academy of Sciences, Vol. 83, Issue 6
https://doi.org/10.1073/pnas.83.6.1896

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
journal, May 1999

Tolis, C.; Peters, G. J.; Ferreira, C. G.
European Journal of Cancer, Vol. 35, Issue 5
https://doi.org/10.1016/S0959-8049(98)00425-0

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Hornik, Vered; Gellerman, Gary; Afargan, Mich El M.
US Patent Document 6,051,554
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6051554

Clinical results of long‐term slow‐release lanreotide treatment of acromegaly
journal, April 1997

Giusti, M.; Ciccarelli, E.; Dallabonzana, D.
European Journal of Clinical Investigation, Vol. 27, Issue 4
https://doi.org/10.1046/j.1365-2362.1997.1190659.x

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions
patent, June 1995

Gansow, Otto A.; Brechbiel, Martin W.; Magerstadt, Michael
US Patent Document 5,428,154
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5428154

A potent cyclic hexapeptide analogue of somatostatin
journal, July 1981

Veber, Daniel F.; Freidinger, Roger M.; Perlow, Debra Schwenk
Nature, Vol. 292, Issue 5818
https://doi.org/10.1038/292055a0

In vitro detection of somatostatin receptors in human tumors
journal, September 1992

Reubi, J. C.; Krenning, E.; Lamberts, S. W. J.
Metabolism, Vol. 41, Issue 9
https://doi.org/10.1016/0026-0495(92)90042-9

Bifunctional chelating agents
patent, October 1991

Johnson, David K.; Kline, Steven J.
US Patent Document 5,057,302
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5057302

Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Frilling, Andrea; Weber, Frank; Saner, Fuat
Surgery, Vol. 140, Issue 6, p. 968-977
https://doi.org/10.1016/j.surg.2006.07.030

Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)
journal, January 1998

Wermuth, C. G.; Ganellin, C. R.; Lindberg, P.
Pure and Applied Chemistry, Vol. 70, Issue 5
https://doi.org/10.1351/pac199870051129

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011

Walrand, Stephan; Barone, Raffaella; Pauwels, Stanislas
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 7, p. 1270-1280
https://doi.org/10.1007/s00259-011-1744-x

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Hornik, Vered; Afargan, Michel; Gellerman, Gary
US Patent Document 6,930,088
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930088

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

Macke, Helmut; Reubi, Jean Claude; Schmitt, Jörg
US Patent Document 7,122,622
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7122622

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
journal, February 1998

Nagy, A.; Schally, A. V.; Halmos, G.
Proceedings of the National Academy of Sciences, Vol. 95, Issue 4
https://doi.org/10.1073/pnas.95.4.1794

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
journal, October 2000

Halmos, Gabor; Sun, Baodong; Schally, Andrew V.
The Journal of Clinical Endocrinology & Metabolism, Vol. 85, Issue 10
https://doi.org/10.1210/jcem.85.10.3509

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
journal, January 1992

Yamada, Y.; Post, S. R.; Wang, K.
Proceedings of the National Academy of Sciences, Vol. 89, Issue 1
https://doi.org/10.1073/pnas.89.1.251

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors
journal, April 2008

Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856
https://doi.org/10.1007/s00259-008-0778-1

Anticancer therapy
patent, April 2017

Norenberg, Jeffrey P.
US Patent Document 9,610,371
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9610371

Combined Modality Therapy of Gemcitabine and Radiation
journal, January 2005

Pauwels, B.
The Oncologist, Vol. 10, Issue 1
https://doi.org/10.1634/theoncologist.10-1-34

Somatostatin Receptors in Pituitary and Development of Somatostatin Receptor Subtype-Selective Analogs
journal, January 2003

Shimon, Ilan
Endocrine, Vol. 20, Issue 3
https://doi.org/10.1385/ENDO:20:3:265

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
journal, August 1993

Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.
European Journal of Nuclear Medicine, Vol. 20, Issue 8
https://doi.org/10.1007/BF00181765

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara
Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71
https://doi.org/10.1089/108497804773391694

Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery
journal, January 1999

Hof land, Leo J.; Breeman, Wout A. P.; Krenning, Eric P.
Proceedings of the Association of American Physicians, Vol. 111, Issue 1
https://doi.org/10.1046/j.1525-1381.1999.09110.x

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

Pless, Miklos; Waldherr, Christian; Maecke, Helmut
Lung Cancer, Vol. 45, Issue 3, p. 365-371
https://doi.org/10.1016/j.lungcan.2004.02.020

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
journal, September 1982

Bauer, Wilfried; Briner, Ulrich; Doepfner, Wolfgang
Life Sciences, Vol. 31, Issue 11
https://doi.org/10.1016/0024-3205(82)90087-X

A Comparison of High- Versus Low-Linear Energy Transfer Somatostatin Receptor Targeted Radionuclide Therapy In Vitro
journal, February 2005

Nayak, Tapan; Norenberg, Jeffrey; Anderson, Tamara
Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, Issue 1
https://doi.org/10.1089/cbr.2005.20.52

Yttrium-90 DOTATOC: first clinical results
journal, October 1999

Otte, A.; Herrmann, R.; Heppeler, A.
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447
https://doi.org/10.1007/s002590050476

The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy
journal, January 1997

Szekeres, Thomas; Fritzer-Szekeres, Monika; Elford, Howard L.
Critical Reviews in Clinical Laboratory Sciences, Vol. 34, Issue 6
https://doi.org/10.3109/10408369709006424

Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides
journal, May 2010

Melis, M.; Vegt, E.; Konijnenberg, M.
Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977
https://doi.org/10.2967/jnumed.109.074310

213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
journal, February 2006

Norenberg, J. P.
Clinical Cancer Research, Vol. 12, Issue 3
https://doi.org/10.1158/1078-0432.CCR-05-1264

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
journal, December 2005

Kaltsas, G. A.; Papadogias, D.; Makras, P.
Endocrine-Related Cancer, Vol. 12, Issue 4
https://doi.org/10.1677/erc.1.01116

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

de Jong, Marion; Valkema, Roelf; Jamar, Francois
Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140
https://doi.org/10.1053/snuc.2002.31027

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors
journal, December 2002

Reubi, Jean Claude; Eisenwiener, Klaus-Peter; Rink, Hans
European Journal of Pharmacology, Vol. 456, Issue 1-3
https://doi.org/10.1016/S0014-2999(02)02651-1

Power-on reset circuit device for multi-level power supply sources
patent, May 1993

Nagai, Nobutaka
US Patent Document 5,214,316
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5214316

Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

Menda, Y.; O'Dorisio, M.; Kao, S.
Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531
https://doi.org/10.2967/jnumed.110.075226

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
journal, September 2000

Heppeler, A.; Froidevaux, S.; Eberle, A.
Current Medicinal Chemistry, Vol. 7, Issue 9
https://doi.org/10.2174/0929867003374516

Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
journal, April 2005

Kwekkeboom, Dik J.; Teunissen, Jaap J.; Bakker, Willem H.
Journal of Clinical Oncology, Vol. 23, Issue 12
https://doi.org/10.1200/JCO.2005.08.066

Octreotide
journal, January 1996

Lamberts, Steven W. J.; van der Lely, Aart-Jan; de Herder, Wouter W.
New England Journal of Medicine, Vol. 334, Issue 4
https://doi.org/10.1056/NEJM199601253340408

Somatostatin Receptor-Based Scintigraphy and Antitumor Treatment--An Expanding Vista?
journal, October 2000

Jensen, R. T.
Journal of Clinical Endocrinology & Metabolism, Vol. 85, Issue 10
https://doi.org/10.1210/jc.85.10.3507

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer
journal, January 1993

Stiefel, Friedrich; Morant, Rudolf
Supportive Care in Cancer, Vol. 1, Issue 1
https://doi.org/10.1007/BF00326640

Peptides
patent, July 1997

Albert, Rainer; Macke, Helmut
US Patent Document 5,650,134
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5650134

Highly sensitive multimeric nucleic acid probes
patent, June 2000

Kool, Eric T.
US Patent Document 6,077,668
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6077668

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark
Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290
https://doi.org/10.1097/MNM.0b013e3282f3d03e

Assessment of Hepatic Toxicity from Treatment with ⁹⁰Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

Bushnell, David; Menda, Yusuf; Madsen, Mark
Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588
https://doi.org/10.1089/108497803322287664

4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET
journal, November 2010

Walrand, S.; Jamar, F.; van Elmbt, L.
Journal of Nuclear Medicine, Vol. 51, Issue 12
https://doi.org/10.2967/jnumed.110.080093

Somatostatin analogs
patent, March 2002

Lister-James, John; Dean, Richard T.; Pearson, Daniel A.
US Patent Document 6,358,491
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6358491

⁹⁰Y-DOTA-D-Phe¹-Try³- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.
Biopolymers, Vol. 66, Issue 6, p. 393-398
https://doi.org/10.1002/bip.10349

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE and ⁹⁰Y-DOTATOC
journal, December 2009

Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa
Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665
https://doi.org/10.1089/cbr.2009.0641

Somatostatin and Its Receptor Family
journal, July 1999

Patel, Yogesh C.
Frontiers in Neuroendocrinology, Vol. 20, Issue 3
https://doi.org/10.1006/frne.1999.0183

Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience
journal, April 2002

Valkema, Roelf; de Jong, Marion; Bakker, Willem H.
Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122
https://doi.org/10.1053/snuc/2002.31025

Similar Records in DOE Patents and OSTI.GOV collections:

Anticancer therapy

Patent Norenberg, Jeffrey P.

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Full Text Available
Method and system for administering internal radionuclide therapy (IRT) and external radiation therapy (XRT)

Patent Sgouros, George; Hobbs, Robert

A computerized method and system for determining an optimum amount of Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) to administer, comprising: obtaining activity image information for an imaged object from a detector; running a Monte Carlo simulation for the activity image information to obtain absorbed dose-rate image information at multiple times; adding the absorbed dose-rate image information from each time to obtain IRT total absorbed dose image information; and utilizing the IRT total dose image information to obtain total dose image information that is equivalent to XRT dose image information in terms of dose-rate, wherein the IRT dosemore » « less
Full Text Available
Scanning systems for particle cancer therapy

Patent Trbojevic, Dejan

A particle beam to treat malignant tissue is delivered to a patient by a gantry. The gantry includes a plurality of small magnets sequentially arranged along a beam tube to transfer the particle beam with strong focusing and a small dispersion function, whereby a beam size is very small, allowing for the small magnet size. Magnets arranged along the beam tube uses combined function magnets where the magnetic field is a combination of a bending dipole field with a focusing or defocusing quadrupole field. A triplet set of combined function magnets defines the beam size at the patient. A scanningmore » « less
Full Text Available
Brain-specific enhancers for cell-based therapy

Patent Visel, Axel; Rubenstein, John L.R.; Chen, Ying-Jiun (Jasmine); ...

Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyzes. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.
Full Text Available
Shape memory polymer foams for endovascular therapies

Patent Wilson, Thomas S.; Maitland, Duncan J.

A system for occluding a physical anomaly. One embodiment comprises a shape memory material body wherein the shape memory material body fits within the physical anomaly occluding the physical anomaly. The shape memory material body has a primary shape for occluding the physical anomaly and a secondary shape for being positioned in the physical anomaly.
Full Text Available

Similar Records

Title: Anticancer therapy

Abstract

Citation Formats

Treatment of damaged bone marrow and dosage units therefor patent, July 1990

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors journal, June 2008

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues journal, November 2009

Somatostatin in the central nervous system: Physiology and pathological modifications journal, January 1986

Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy journal, August 2003

Biochemical and Functional Properties of Somatostatin Receptors journal, June 1992

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues journal, July 2009

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats journal, September 2006

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone journal, January 1973

Hypothalamic hormones: from neuroendocrinology to cancer therapy journal, January 1994

Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype journal, September 1993

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study journal, July 2001

RGD (Arg-Gly-Asp) coupled to (neuro)peptides patent, April 2007

Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study journal, July 1996

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides journal, April 1993

Somatostatin analogs for the treatment of cancer patent, November 2001

Cyclic peptide somatostatin analogs patent, August 1999

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. journal, March 1986

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines journal, May 1999

Conformationally constrained backbone cyclized somatostatin analogs patent, April 2000

Clinical results of long‐term slow‐release lanreotide treatment of acromegaly journal, April 1997

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions patent, June 1995

A potent cyclic hexapeptide analogue of somatostatin journal, July 1981

In vitro detection of somatostatin receptors in human tumors journal, September 1992

Bifunctional chelating agents patent, October 1991

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors journal, December 2006

Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) journal, January 1998

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts journal, February 2011

Conformationally constrained backbone cyclized somatostatin analogs patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors patent, October 2006

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin journal, February 1998

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors journal, October 2000

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. journal, January 1992

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors journal, April 2008

Anticancer therapy patent, April 2017

Combined Modality Therapy of Gemcitabine and Radiation journal, January 2005

Somatostatin Receptors in Pituitary and Development of Somatostatin Receptor Subtype-Selective Analogs journal, January 2003

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients journal, August 1993

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas journal, February 2004

Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery journal, January 1999

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial journal, September 2004

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action journal, September 1982

A Comparison of High- Versus Low-Linear Energy Transfer Somatostatin Receptor Targeted Radionuclide Therapy In Vitro journal, February 2005

Yttrium-90 DOTATOC: first clinical results journal, October 1999

The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy journal, January 1997

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides journal, May 2010

213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model journal, February 2006

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues journal, December 2005

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings journal, April 2002

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors journal, December 2002

Power-on reset circuit device for multi-level power supply sources patent, May 1993

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors journal, September 2010

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides journal, September 2000

Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors journal, April 2005

Octreotide journal, January 1996

Somatostatin Receptor-Based Scintigraphy and Antitumor Treatment--An Expanding Vista? journal, October 2000

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer journal, January 1993

Peptides patent, July 1997

Highly sensitive multimeric nucleic acid probes patent, June 2000

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide journal, January 2008

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases journal, August 2003

4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET journal, November 2010

Somatostatin analogs patent, March 2002

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies journal, January 2002

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC journal, December 2009

Somatostatin and Its Receptor Family journal, July 1999

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience journal, April 2002

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Preclinical Evaluation of the α-Particle Generator Nuclide ²²⁵Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
journal, June 2008

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

Somatostatin in the central nervous system: Physiology and pathological modifications
journal, January 1986

Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
journal, August 2003

Biochemical and Functional Properties of Somatostatin Receptors
journal, June 1992

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

Long-term toxicity of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in rats
journal, September 2006

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
journal, January 1973

Hypothalamic hormones: from neuroendocrinology to cancer therapy
journal, January 1994

Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype
journal, September 1993

The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study
journal, July 1996

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
journal, April 1993

Somatostatin analogs for the treatment of cancer
patent, November 2001

Cyclic peptide somatostatin analogs
patent, August 1999

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
journal, March 1986

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
journal, May 1999

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Clinical results of long‐term slow‐release lanreotide treatment of acromegaly
journal, April 1997

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions
patent, June 1995

A potent cyclic hexapeptide analogue of somatostatin
journal, July 1981

In vitro detection of somatostatin receptors in human tumors
journal, September 1992

Bifunctional chelating agents
patent, October 1991

Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)
journal, January 1998

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
journal, February 1998

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
journal, October 2000

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
journal, January 1992

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors
journal, April 2008

Anticancer therapy
patent, April 2017

Combined Modality Therapy of Gemcitabine and Radiation
journal, January 2005

Somatostatin Receptors in Pituitary and Development of Somatostatin Receptor Subtype-Selective Analogs
journal, January 2003

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
journal, August 1993

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery
journal, January 1999

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
journal, September 1982

A Comparison of High- Versus Low-Linear Energy Transfer Somatostatin Receptor Targeted Radionuclide Therapy In Vitro
journal, February 2005

Yttrium-90 DOTATOC: first clinical results
journal, October 1999

The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy
journal, January 1997

Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides
journal, May 2010

213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
journal, February 2006

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
journal, December 2005

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors
journal, December 2002

Power-on reset circuit device for multi-level power supply sources
patent, May 1993

Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
journal, September 2000

Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
journal, April 2005

Octreotide
journal, January 1996

Somatostatin Receptor-Based Scintigraphy and Antitumor Treatment--An Expanding Vista?
journal, October 2000

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer
journal, January 1993

Peptides
patent, July 1997

Highly sensitive multimeric nucleic acid probes
patent, June 2000

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

Assessment of Hepatic Toxicity from Treatment with ⁹⁰Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET
journal, November 2010

Somatostatin analogs
patent, March 2002

⁹⁰Y-DOTA-D-Phe¹-Try³- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE and ⁹⁰Y-DOTATOC
journal, December 2009

Somatostatin and Its Receptor Family
journal, July 1999

Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience
journal, April 2002